Skip to main content

Apple (AAPL) - Get Apple Inc. Report soared 6 11/16 to 127 13/16 in postclose Island action after posting second-quarter earnings of 88 cents a diluted share, beating the 19-analyst estimate of 81 cents and up from the year-ago 84 cents which includes items. Revenues rose to 27% to $1.94 billion from $1.53 billion and gross margins rose to 28.2%, up from 26.3% a year ago. The company also set a 2-for-1 stock split.

For more on Apple's

earnings, check out coverage from

joint newsroom.

In other postclose news (

earnings estimates from First Call/Thomson Financial; earnings reported on a diluted basis unless otherwise specified


Earnings/revenue reports and previews

E-commerce leader

Commerce One


said its first-quarter losses were 9 cents a share, which beat the 19-analyst estimate of a loss of 12 cents for the quarter and matched the year-ago per-share results. Earnings were adjusted for its 2-for-1 stock split effective today.

For more on Commerce One's

earnings, check out coverage from

joint newsroom.

TheStreet Recommends


(CNET) - Get ZW Data Action Technologies Inc Report

reported first-quarter earnings of 2 cents a share, surprising analysts who had expected a loss of 6 cents. The company said strong growth in traffic was responsible for the unexpectedly profitable quarter. CNET Networks expects to stay in the black for all of 2000. Previously, the company had predicted operating income only for the fourth quarter


(ATHM) - Get Autohome Inc. Report

reported a first-quarter pro forma loss of 1 cent a share, short of Wall Street's expectations that it would break even but narrower than the year-earlier pro forma loss of 2 cents a share. The Internet-service company posted a net loss of $676.5 million, or $1.75 a share, compared with a loss of $18.1 million, or 8 cents, in the 1999 quarter. Revenue rose 75% in the latest quarter, to $138 million, from $78.7 million a year earlier. The company said the number of new subscribers had more than tripled, to 1.5 million.



reported first-quarter earnings of 10 cents a share, better than the five-analyst estimate of 8 cents . The company said when 307 million shares are assumed outstanding, earnings before charges are 9 cents a share. Excluding a gain, year-ago earnings were 3 cents a share.


(PYX) - Get Pyxus International, Inc. Report

posted first-quarter earnings of 25 cents a share, in line with the five-analyst estimate and up from the year-ago 22 cents a share. The company said earnings before amortization of intangibles were 32 cents in the latest first quarter compared with 29 cents a year ago.

Ticketmaster Online-CitySearch


posted a first-quarter loss of 14 cents a share, excluding goodwill. The results are wider than the year-ago report of an 8-cent loss. The three-analyst estimate, which included goodwill, expected the company to report a 58-cent loss.

Mergers, acquisitions and joint ventures


(CI) - Get Cigna Corporation Report


Cigna HealthCare


Cardinal Health

(CAH) - Get Cardinal Health, Inc. Report

said Cigna expects to purchase nearly $3 billion of pharmaceuticals from Cardinal over the next three years.


(WMT) - Get Walmart Inc. Report

said it increased its ownership of Mexico's largest retailer,

Wal-Mart de Mexico

, by 6% to almost 60% for about $600 million.

Offerings and stock actions

Citizens Utilities


authorized the repurchase of up to $100 million of its common stock. The company also said in a statement that it authorized the purchase of up to $25 million of

Electric Lightwave


. Electric Lightwave is an 82%-owned subsidiary of Citizens.

Clayton Homes


said it approved a 15-million share buyback.

Goldman Sachs

priced 46.3 million shares of



at $14 each, the top of the expected $12 to $14 range. The Vancouver, British Columbia-based company builds fiber-optic networks.



set a 2-for-1 stock split.


Following an earlier announcement from

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

that it voluntarily

pulled an FDA application for its hypertension drug


, the company said four patients among thousands in clinical trials required breathing tubes because of severe reactions to the medicine.